Shots:
- The US FDA has approved Ozempic to reduce the risk of kidney disease worsening & CV death in adults with type 2 diabetes & CKD
- Approval was based on P-IIIb (FLOW) trial assessing Ozempic (1mg, Q1W, n=1767) vs matching PBO (n=1766) in type 2 diabetes & CKD pts (N=3533)
- Study met its 1EP of 24% relative risk reduction in kidney disease progression, kidney failure, & CV death with 4.9% absolute risk reduction at 3yrs.
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
